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Abstract
Our previous studies show reduced abundance of the β-subunit of mitochondrial H+-ATP
synthase (β-F1-ATPase) in skeletal muscle of obese individuals. The β-F1-ATPase forms
the catalytic core of the ATP synthase, and it is critical for ATP production in muscle. The
mechanism(s) impairing β-F1-ATPase metabolism in obesity, however, are not completely
understood. First, we studied total muscle protein synthesis and the translation efficiency of
β-F1-ATPase in obese (BMI, 36±1 kg/m2) and lean (BMI, 22±1 kg/m2) subjects. Both total
protein synthesis (0.044±0.006 vs 0.066±0.006%h-1) and translation efficiency of β-F1-
ATPase (0.0031±0.0007 vs 0.0073±0.0004) were lower in muscle from the obese subjects
when compared to the lean controls (P<0.05). We then evaluated these same responses in
a primary cell culture model, and tested the specific hypothesis that circulating non-esteri-
fied fatty acids (NEFA) in obesity play a role in the responses observed in humans. The find-
ings on total protein synthesis and translation efficiency of β-F1-ATPase in primary
myotubes cultured from a lean subject, and after exposure to NEFA extracted from serum of
an obese subject, were similar to those obtained in humans. Among candidate microRNAs
(i.e., non-coding RNAs regulating gene expression), we identified miR-127-5p in preventing
the production of β-F1-ATPase. Muscle expression of miR-127-5p negatively correlated
with β-F1-ATPase protein translation efficiency in humans (r = – 0.6744; P<0.01), and could
be modeled in vitro by prolonged exposure of primary myotubes derived from the lean sub-
ject to NEFA extracted from the obese subject. On the other hand, locked nucleic acid inhib-
itor synthesized to target miR-127-5p significantly increased β-F1-ATPase translation
efficiency in myotubes (0.6±0.1 vs 1.3±0.3, in control vs exposure to 50 nM inhibitor;
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P<0.05). Our experiments implicate circulating NEFA in obesity in suppressing muscle pro-
tein metabolism, and establish impaired β-F1-ATPase translation as an important conse-
quence of obesity.
Introduction
The increasing prevalence of obesity is a major health concern due to its associated physiologi-
cal and metabolic consequences. Obesity, whose cardinal characteristic is excess adiposity, is
associated with increase in various health risk factors linked to cardiovascular disease and type
2 diabetes [1]. Fatty acids in obesity originating from either plasma or muscle triacylglycerol
deposits are implicated in impaired glucose metabolism in skeletal muscle [2]. In addition to
its effects on the cardiovascular system and impaired glucose metabolism, obesity also perturbs
muscle protein synthesis [3,4]. The precise mechanism(s) reducing protein synthesis in muscle
in obesity are not completely understood. Factors associated with obesity such as insulin resis-
tance, inflammation, and oxidative stress may contribute to impaired muscle protein metabo-
lism in the post-absorptive state [5]. Also, it is possible that fatty acids, either directly or
indirectly via their effects on inducing insulin resistance, may reduce protein synthesis in mus-
cle in obesity. We have shown that acute increase in plasma non-esterified fatty acid (NEFA)
availability induced by the intravenous infusion of a fat emulsion, although it induced insulin
resistance, did not impair the muscle anabolic response to amino acids [6], which suggests dis-
association between NEFA-mediated insulin resistance and muscle protein metabolism. How-
ever, elevation of NEFA in the basal state impairs muscle protein synthesis [7], indicating a
role of plasma NEFA in decreasing muscle protein metabolism in the post-absorptive state.
Also, in an animal model of dietary fat-induced obesity, reduced muscle protein synthesis is
observed concomitant with increased lipid infiltration in muscle [8]. Taken together, the latter
evidence suggests that muscle lipid exposure, which can be either through plasma NEFA or via
the action of lipoprotein lipase in circulating triacylglycerols, or triacylglycerol-associated fatty
acids from adipocytes interspersed between muscle fibers, can impair muscle protein metabo-
lism in the setting of obesity.
Obesity is associated with reduced abundance of mitochondrial proteins, including the H
+-ATP synthase complex [9] involved in muscle ATP production. In line with such evidence,
muscle ATP metabolism is impaired in obesity/insulin resistance [10,11], and the expression
specifically of the beta subunit of mitochondrial H+-ATP synthase (β-F1-ATPase), which cata-
lyzes the conversion of ADP to ATP, is reduced in the muscle from obese individuals [12]. In
liver tissue, reduced β-F1-ATPase has been linked to abnormal ATP content in animal models
[13]. Therefore, understanding the metabolism of β-F1-ATPase has important physiological
implications in explaining energy homeostasis in muscle in obesity. Although protein abun-
dance is determined by multiple factors, mRNA translation has a primary role in controlling
protein expression in skeletal muscle [14], including that of β-F1-ATPase [15,16]. Translation
of mRNA can be regulated by epigenetic mechanisms, i.e. DNA methylation, histone modifica-
tions, and microRNAs (miRNAs), which allow for long-term adaptations to distinct environ-
mental and physiological challenges.
The β-F1-ATPase is a nuclear encoded enzyme (ATP5B), and the synthesis of β-F1-ATPase
is known to be subject to regulation by 3’UTR binding factors [17–19]. miRNAs can bind to
the 3’UTR of mRNA transcripts and silence translation through several mechanisms such as
targeting degradation of the mRNA or blocking translation [20–22]. The latter has been
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reported for the β-F1-ATPase during cellular development and tumorigenesis [19,23]. More
specifically, miR-101-3p and miR-127-5p target the β-F1-ATPase mRNA and inhibit transla-
tion without affecting mRNA content. The role of miRNAs in controlling β-F1-ATPase pro-
duction has not been evaluated in human skeletal muscle or linked to obesity.
The goal of the current study was to investigate putative mechanisms impairing muscle pro-
tein, and specifically β-F1-ATPase, metabolism in obesity. We hypothesized that the plasma
NEFA profile associated with obesity reduces total protein synthesis in muscle, and at the single
protein level suppresses the translation efficiency of β-F1-ATPase, and that the latter effect is
mediated by miRNAs. Our investigation was divided into three experimental series: i) deter-
mine the effects of obesity on skeletal muscle total protein synthesis and the translation effi-
ciency of β-F1-ATPase, ii) quantify effects on protein metabolism after exposing primary
culture myotubes from a lean subject to NEFA extracted from serum of an obese subject, and
iii) explore miRNAs as putative intermediates regulating muscle β-F1-ATPase translation.
Materials and Methods
Human subjects
The protocol and consent form were approved by the Institutional Review Board (IRB) at
Mayo Clinic (IRB #12–004000). All participants provided written informed consent, following
a consent procedure approved by the IRB. Healthy, sedentary lean (n = 6, BMI<25) and obese
(n = 7, BMI>30) subjects were studied at the Clinical Studies Infusion Unit (CSIU) in Mayo
Clinic, Scottsdale, AZ, after screening that included physical examination, medical history, and
routine blood and urine analyses. Prior to their physical screening visit, subjects were screened
over the phone about medications and supplements that might affect protein, glucose, or fat
metabolism. None of the subjects included in the study were taking any medications or supple-
ments. Fasting glucose (YSI analyzer, Yellow Springs, OH) and insulin (ELISA kit, ALPCO
Diagnostics, Windham, NH) levels were used to calculate a HOMA-IR [24]. Plasma amino
acid concentrations were quantified by high performance liquid chromatography (HPLC) [25]
and NEFA by HPLC-mass spectrometry (HPLC-MS) [26]. Body fat percentage (BF %) and fat
free mass (FFM) were determined using bioimpedance analysis (BIA 310e, Biodynamics Corp.,
Shoreline, WA). Subject characteristics are shown in Table 1. Dietary intake (three-day diet
record; Table 2) was analyzed using The Food Processor Nutrition Analysis Software (ESHA
Research, Salem, OR). Serum NEFA concentrations of the study participants are shown in
Table 3.
Infusion protocol and tissue collection
Details of the protocol used to measure total muscle protein synthesis are described previously
[6,27]. Briefly, subjects arrived at the CSIU the morning of the study after a 10-hr overnight
fast. An intravenous line was inserted into an antecubital vein for infusions and another one in
a retrograde fashion into a dorsal metacarpal vein in the contralateral hand for arterialized
blood sampling. Patency was maintained by slow infusion of normal saline. A primed (2.7
umolkg-1) continuous (0.05 umolkg-1min-1) infusion of L-[ring-13C6]phenylalanine ([13C6]
phe; Cambridge Isotope Laboratories, Inc., Andover, MA) tracer was administered for five
hours. Blood samples were collected before the initiation of any infusions, and every fifteen
minutes starting at 1.5 hours after the initiation of the tracer infusion. Muscle biopsies were
collected at two and five hours after the initiation of the tracer. Percutaneous muscle biopsies
(~80 mg) were collected from the vastus lateralismuscle using a Bergström cannula. Blood and
muscle samples were processed as previously described [28], and enrichments of [13C6]phe in
blood and protein-bound amino acids in muscle were determined using LC-MS/MS [29].
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Enrichment was expressed as molar percent excess. The fractional synthesis rate (FSR; %h-1)
of total muscle protein was calculated as described in the S1 Appendix.
Primary tissue culture and non-esterified fatty acid extraction
Tissue culture conditions, reagent sources, and procedures have been previously described
[30,31]. The experimental procedures used for tissue culture together with the NEFA extrac-
tion used in the tissue culture experiments are described in detail in the S1 Appendix. Differen-
tiated myotubes were exposed to NEFA for a period of one week. As opposed to short term
(i.e., hours) culture of differentiated myotubes with lipids [32], typical in cell culture experi-
ments, exposure of the differentiated myotubes to NEFA for a week represents a more physio-
logical in vivo circumstance, and where muscle cells are exposed to lower lipid concentrations
but for a rather longer period of time.
Quantification of mRNA/miRNA and protein
For the extraction and quantification of mRNA we used procedures we have previously
described [33–35]. Proteins were simultaneously extracted from QIAzol lysates following a
protocol adapted from Simões et al. [36]. Details of both the mRNA/miRNA and protein quan-
tification are described in the S1 Appendix.
Concurrent glucose uptake and protein synthesis
Simultaneous glucose uptake and protein synthesis in the cell culture experiments were deter-
mined using the fluorescent glucose analogue 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)
amino]-D-glucose) and puromycin analogue O-propargyl-puromycin, respectively. Details are
provided in the S1 Appendix.
Table 1. Subject characteristics.
Lean Obese
Gender (M/F) 3M / 3F 4M / 3F
Age (years) 33 ± 5 39 ± 4
BMI (kg/m2) 22 ± 1 36 ± 1‡
Height (cm) 171 ± 5 171 ± 3
Weight (kg) 65 ± 6 108 ± 7‡
Body Fat (%) 22 ± 3 36 ± 2†
Lean Body Mass (kg) 52 ± 6 69 ± 4*
HDL Cholesterol (mM) 1.8 ± 0.2 1.0 ± 0.1‡
Total Cholesterol (mM) 4.1 ± 0.3 4.9 ± 0.3*
Triacylglycerols (mM) 0.6 ± 0.1 2.6 ± 0.6†
Glucose (mM) 4.9 ± 0.2 5.4 ± 0.3
Insulin (pM) 29 ± 3 101 ± 14‡
HOMA-IR 0.9 ± 0.1 3.2 ± 0.7†
HbA1c (%) 5.5 ± 0.1 5.7 ± 0.1
Data are means ± SE
* P<0.05
† P<0.01
‡ P<0.001 vs lean control subjects
doi:10.1371/journal.pone.0160057.t001
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Inhibition of miR-127-5p experiments and exosome isolation
Details of the experiments for the inhibition of miR-127-5p, as well as the procedures used for
the isolation of exosomes in serum are provided in the S1 Appendix.
DNAmethylation
DNAmethylation was assessed using the sodium bisulfite sequencing method following proce-
dures we have previously described [33], and the exact details are described in the S1
Appendix.
Statistical analyses
Data reported are mean±standard error (SE) and significance was determined at the P0.05
level. Statistical significance was calculated using a one-way analysis of variance (ANOVA)
Table 2. Dietary analysis.
Lean (n = 6) Obese (n = 6)
Protein (%) 16.5 ± 1.3 14.7 ± 1.3
Carbohydrates (%) 47.2 ± 4.0 44.2 ± 4.5
Fat (%) 35.5 ± 3.5 41.2 ± 4.8
Saturated Fat (%) 10.1 ± 1.4 13.9 ± 1.6*
Monosaturated Fat (%) 9.0 ± 1.6 6.3 ± 1.9
Polyunsaturated Fat (%) 6.6 ± 1.2 3.2 ± 1.2*
Trans Fatty Acid (%) 0.7 ± 0.2 0.6 ± 0.2
Other Fat (%) 8.2 ± 1.4 17.2 ± 4.7*
GramWeight (g) 2909 ± 312 2772 ± 201
Calories (kcal) 3240 ± 343 3455 ± 661
Calories from Fat (kcal) 1236 ± 170 1487 ± 421
Calories from Sat Fat (kcal) 332 ± 76 474 ± 101
Protein (g) 122 ± 16 120 ± 13
Carbohydrates (g) 368 ± 55 392 ± 81
Dietary Fiber (g) 27.6 ± 2.7 21.8 ± 3.9
Soluble Fiber (g) 1.9 ± 0.4 0.6 ± 0.3†
Total Sugars (g) 116 ± 23 122 ± 27
Monosaccharides (g) 18.5 ± 2.9 6.4 ± 1.3†
Disaccharides (g) 38.7 ± 20.3 20.8 ± 5.2
Other Carbohydrates (g) 176 ± 30 170 ± 50
Fat (g) 123 ± 24 165 ± 47
Saturated Fat (g) 36.9 ± 8.5 52.7 ± 11.2
Monosaturated Fat (g) 33.9 ± 9.7 18.6 ± 3.5
Polyunsaturated Fat (g) 23.7 ± 6.0 8.9 ± 2.5*
Trans Fatty Acid (g) 2.5 ± 0.9 1.7 ± 0.4
Cholesterol (mg) 518 ± 120 393 ± 55
Water (g) 1466 ± 309 1507 ± 138
Omega-3 Fatty Acid (g) 1.7 ± 0.5 1.1 ± 0.3
Omega-6 Fatty Acid (g) 19.3 ± 5.6 7.4 ± 2.3*
Data are means ± SE
* P<0.05
† P<0.01 vs lean control subjects.
doi:10.1371/journal.pone.0160057.t002
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with Tukey’s posthoc test for multiple comparisons, or an unpaired Student’s t-test for two-
population comparison. A two-way repeated measures-ANOVA (RM-ANOVA) with Bonfer-
roni correction for multiple comparisons was used for all two-factor analyses. Correlation was
determined by calculating a Pearson product-moment correlation coefficient (r). Equality of
sample variance and normality were determined using an F-test and Shapiro-Wilk test, respec-
tively. Statistical calculations were made using Graphpad Prism Software (ver 6.0b; La Jolla,
CA).
Results
Skeletal muscle protein synthesis, dietary analysis and circulating NEFA
profile
We found reduced rate of total protein synthesis in skeletal muscle in obese subjects compared
to lean controls (t(11) = 2.608; P = 0.012; Fig 1A). We also measured the concentration of
plasma amino acids, whose availability regulates muscle protein synthesis. Analysis of the
plasma amino acid concentrations revealed an effect of obesity, and many of the measured
amino acids were significantly elevated in the obese individuals compared to lean controls (Fig
1B).
Although caloric intake was not different between lean and obese subjects, we found trends
in the types of dietary fats consumed (Table 2). Differences in the percent contribution of poly-
unsaturated and saturated fats in the diet were also reflected in the circulating NEFA of the two
subject populations. For example, the ratio of polyunsaturated fatty acids (PUFA) to saturated
fatty acids (SFA) (i.e., PUFA/SFA) was significantly lower in the obese subjects (Table 3). We
hypothesized that the specific circulating NEFA profile in our obese subjects suppresses muscle
protein metabolism. Thus, we explored whether the NEFA profile of our obese subjects sup-
presses protein metabolism in primary muscle cells from a lean subject and when compared to
the NEFA profile typical of the lean phenotype. Extracted serum NEFA from representative
Table 3. Circulating non-esterified fatty acids (uM).
Lean (n = 6) Obese (n = 7)
Myristic 14:0 5.6 ± 0.6 6.6 ± 0.6
Palmitic 16:0 143 ± 11 157 ± 10
Palmitoleic 16:1 cis 10.3 ± 1.5 10.1 ± 1.0
Stearic 18:0 72.3 ± 5.3 79.2 ± 5.7
Oleic 18:1 cis 198 ± 21 185 ± 12
Elaidic 18:1 trans 5.5 ± 0.5 7.9 ± 0.9*
Linoleic 18:2 (n-6) 109 ± 6 88 ± 8*
Linolenic 18:3 (n-3) 9.2 ± 1.3 7.5 ± 0.9
Arachidonic 20:4 (n-6) 4.0 ± 0.3 3.5 ± 0.6
PUFA 122 ± 7 99 ± 9*
MUFA 214 ± 22 203 ± 13
SFA 221 ± 10 243 ± 13
PUFA/SFA 0.55 ± 0.02 0.41 ± 0.04†
Total 557 ± 37 545 ± 29
Data are means ± SE
* P<0.05
† P<0.01, vs lean control subjects
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids.
doi:10.1371/journal.pone.0160057.t003
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subjects from our pool of lean and obese subjects studied during the in vivo determination of
total muscle protein synthesis were used to represent obese (i.e., Obese NEFA) and lean (i.e.,
Lean NEFA) NEFA profiles. The representative obese and lean subjects whose NEFA were
used in the cell culture experiments (Table 4; right), were selected on the basis of how well their
circulating NEFA profiles reflected the average circulating NEFA profiles of our obese and lean
subjects, respectively, and as shown in Table 4 (left). Because generally PUFA (i.e., omega-3
fatty acids [37]), or arachidonic acid [38,39] have been linked to favorable effects on muscle
protein metabolism, NEFA were also extracted from the serum of a lean subject with relatively
higher PUFA concentrations and PUFA/SFA ratio among the lean subjects (i.e., Lean
NEFA(P)). These NEFA were used to evaluate the specific effects of increased contribution of
PUFA to circulating NEFA on muscle protein metabolism.
Exposure of primary human myotubes to NEFA
Differentiated myotubes propagated from a muscle biopsy sample that was obtained from a
healthy lean subject were treated with three separate NEFA-containing media, and following
the experimental protocol shown in S1A Fig. NEFA extracted from the collected serum of a sin-
gle, representative lean subject (i.e., Lean NEFA), from a single lean subject with relatively
higher PUFA/SFA ratio (i.e., Lean NEFA(P)), and a single, representative obese subject (i.e.,
Obese NEFA). The plasma NEFA profiles associated with the three subjects are shown in
Fig 1. Decreased total protein synthesis in muscle and increased amino acid concentrations in
plasma in obese subjects. (A) Fractional synthesis rate (FSR) for total muscle protein in the lean (BMI<25)
and obese (BMI>30) subjects. (B) Fasting plasma amino acid concentrations. Data shown are means ±SE,
and significance was *P<0.05, **P<0.01, and ***P<0.001 by Student’s unpaired t-test.
doi:10.1371/journal.pone.0160057.g001
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Table 4 (right). We observed no qualitative differences in myotube viability or morphology
across the cell culture experiments associated with the three NEFA treatments (S1B Fig).
When compared to VEH, basal glucose uptake decreased significantly following the treat-
ment of the myotubes with Lean NEFA or Obese NEFA (F(3,20) = 2.952; P<0.05), but there was
no difference between VEH and Lean NEFA(P) or between Obese NEFA and Lean NEFA
(P>0.05; Fig 2A; left). Further analyses revealed significant effect of the type of NEFA treat-
ment on myotybes on GLUT-4 expression (S2A Fig), p-IRS-1 (Tyr895) (S2B Fig) and triacyl-
glycerol accumulation (S2C Fig).
Each NEFA treatment decreased protein synthesis compared to VEH (F(3,20) = 6.994;
P<0.01), but unlike glucose uptake, the Obese NEFA produced greater suppression of protein
synthesis relative to the other NEFA treatments (Fig 2A; right). Treatment with Obese NEFA
Table 4. Circulating non-esterified fatty acids in the lean and obese subjects (left two columns), and in three subjects whose non-esterified fatty
acids extracted for tissue culture experiments (right three columns).
Lean Obese VEH Lean NEFA Lean NEFA(P) Obese NEFA
Palmitic (%) 25.7 ± 0.7 28.8 ± 0.6† 21.3 27.3 26.3 29.9
Oleic (%) 35.1 ± 1.7 33.8 ± 0.7 31.8 36.7 38.2 31.7
Elaidic (%) 1.0 ± 0.1 1.4 ± 0.2* 1.7 1.2 0.9 1.6
Linoleic (%) 19.6 ± 0.5 16.1 ± 1.1† 20.9 18.7 18.9 18.7
MUFA (uM) 214 ± 22 203 ± 13 127 244 281 213
PUFA (um) 122 ± 7 99 ± 9* 82 128 144 126
SFA (uM) 221 ± 10 243 ± 13 150 241 250 263
PUFA/SFA 0.55 ± 0.02 0.41 ± 0.04† 0.55 0.53 0.58 0.48
Total (uM) 557 ± 37 545 ± 29 359 613 675 602
Data are means ± SE for the Lean and Obese
* P<0.05
† P<0.01 vs lean control subjects.
VEH, vehicle, NEFA, non-esterified fatty acids; Lean NEFA, NEFA from a lean subject; Lean NEFA(P), NEFA from a lean subject with higher content of
PUFA; Obese NEFA, NEFA from an obese subject; MUFA, monounsaturated fatty acids (sum of palmitoleic acid, oleic acid, and elaidic acid); PUFA,
polyunsaturated fatty acids (sum of linoleic acid, α-linolenic acid, and arachidonic acid); SFA, saturated fatty acids (sum of myristic acid, palmitic acid, and
stearic acid).
doi:10.1371/journal.pone.0160057.t004
Fig 2. Concurrent assessment of glucose uptake and nascent protein synthesis in primary human
myotubes reveals independent regulatory mechanisms. (A) Average responses for glucose uptake and
protein synthesis. (B) Corresponding recovery experiments for myotubes exposed to Obese NEFA (Pre) and
then incubated for an additional five days in normal growth media (Post). Data shown are means ±SE, n = 6
replicates/group, 10−3 cells/experiment, *P<0.05, **P<0.01, and ***P<0.001 by Student’s unpaired t-test or
one-way ANOVA with Tukey’s posthoc analysis.
doi:10.1371/journal.pone.0160057.g002
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significantly decreased protein synthesis compared to Lean NEFA or Lean NEFA(P) treatments.
A separate group of myotubes were exposed to Obese NEFA as above, but the media was
removed following treatment and replaced with normal growth media. After five days of recov-
ery, there was significant increase in glucose uptake (t(10) = 3.759; P<0.01) in cells following
removal of NEFA (Post) compared with prior to recovery (Pre) (Fig 2B, left). There was no sig-
nificant difference in protein synthesis following removal of NEFA compared with prior to
recovery (P>0.05; Fig 2B; right). Gating parameters, representative intensity traces, and scat-
terplots of each group associated with the above experiments are illustrated in S3 Fig. Scatter-
plots (S3B Fig) depict the emergence of a distinct population of cells that have approximately
the same range of glucose uptake, but shifted towards lower protein synthesis.
Molecular markers of myogenesis
The molecular markers MyoD1 and myogenin mRNA were used to determine quantitative
changes in proliferative myoblasts or differentiating myotubes, respectively. There was a signif-
icant 2.763 ± 0.6062 fold increase (t(11) = 2.642; P = 0.01) in MyoD1 mRNA expression in skel-
etal muscle of obese relative to lean subjects (Fig 3A), but no significant difference (t(11) =
0.1344; P = 0.4492) in myogenin mRNA expression (Fig 3B). In response to prolonged expo-
sure to serum NEFA, there was significant effect of treatment (F(3,20) = 3.208; P = 0.0451) on
myoblast proliferation, with Obese NEFA increasing MyoD1 mRNA expression compared to
VEH, Lean NEFA and Lean NEFA(P) treatments (Fig 3C). No change was observed with Lean
or Lean(P) treatment compared to VEH. There was no significant effect of prolonged exposure
to NEFA on myogenin mRNA expression (F(3,20) = 0.7699; P = 0.5243; Fig 3D). MyoD1
mRNA is expressed in greater abundance in fast glycolytic muscle compared to fast oxidative
or slow oxidative muscle fibers [40,41]. Since obesity is associated with fiber type switching
towards fast glycolytic and low oxidative fibers [42], the observed increase in MyoD1 could
potentially be due to a fiber type switch, at least in vivo. However, MyoD1 also accumulates in
non-quiescent satellite cells, such as in regenerating muscle [43], and therefore we further
examined the individual cell populations.
Targeting distinct cell populations
To address possible differences in myogenesis, a fusion index was used to subtype the myo-
tubes based on the degree of differentiation [44], and modified for total DNA content in lieu of
nuclei quantity. The gating criteria shown in Fig 3E were based on cell frequency clusters at
increasing fluorescent (DNA content) intensities, which was consistent across all experiments.
Cells that were within the initial size and granulation gate, but were excluded from analysis via
the second low glucose/protein synthesis gate, were defined as Type I cells. Population percent-
ages are summarized in Fig 3F. The NEFA treatment only affected Type I cells with Obese
NEFA (P = 0.0490; F(9, 60) = 2.049) and significantly increased the percentage of Type I cells
compared to treatments with VEH and Lean NEFA. Glucose uptake (Fig 3G) and protein syn-
thesis (Fig 3H) were further analyzed per cell population. There was a significant effect of treat-
ment (P = 0.0119; F(3, 20) = 4.731), cell type (P<0.001; F(2, 40) = 239.1), and interaction
(P<0.01; F(6, 40) = 4.419). All treatments reduced glucose uptake in Type IV cells when com-
pared to VEH, but there was no significant difference between treatments (P>0.05). These
results indicate that Type IV cells, with the most nuclear content and metabolically more
active, drive the differences in glucose uptake. There was a significant effect of treatment
(P = 0.0161; F(3, 20) = 4.365), cell type (P<0.001; F(2, 40) = 96.80), and interaction (P = 0.0146;
F(6, 40) = 3.065) on protein synthesis. Specifically, there was lower protein synthesis in Type IV
cells treated with Obese NEFA when compared to VEH, Lean NEFA or Lean NEFA(P)
Fatty Acids and Mitochondrial ATP Synthase β Subunit Metabolism
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Fig 3. Assessment of growth and differentiation parameters suggest different responses between NEFA exposure
groups. (A&C) MyoD1mRNA was quantified as a marker of myoblast proliferation, and (B&D) myogenin mRNA was used
as a marker of myotube differentiation in muscle biopsy or primary culture samples, respectively. (E) A modified fusion index
was determined for each cell based on DNA content and categorized based on frequency clusters. (F) Percentages of cells
identified in each fusion category were compared. Individual cell populations were analyzed for glucose uptake (G) and
nascent protein synthesis (H). Data shown are means ±SE, n = 6 replicates/group, *P<0.05, **P<0.01, and ***P<0.001 by
one-way ANOVA with Tukey’s posthoc or two-way ANOVA with Bonferroni’s posthoc analysis.
doi:10.1371/journal.pone.0160057.g003
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treatments. In contrast to glucose uptake, the resolution of treatment group differences in
cumulative protein synthesis diminished when separated into individual cell types. Our data
suggest that the effects of NEFA treatment on protein synthesis are not specific towards a single
population of cells and to the same extent as seen with the glucose uptake.
β-F1-ATPase protein translation efficiency
We focused our attention on β-F1-ATPase to isolate an important protein in energy metabo-
lism that its activity can be influenced by changes in protein abundance. We found a significant
(t(11) = 2.121; P = 0.0287) 1.83±0.31 fold increase in ATP5BmRNA expression in obese indi-
viduals compared to lean (Fig 4A; left). In order to determine whether increased mRNA
expression is a universal response with respect to mRNAs encoding subunits in the ATP
synthase complex in obesity, we evaluated the mRNA expression of ATP5E, which encodes the
epsilon subunit of the ATP synthase, in a subset of subjects. However, there was no significant
difference (t(11) = 0.4496; P = 0.3381) in the expression of ATP5EmRNA between lean and
obese subjects (Fig 4A; right). Calculated Pearson’s product-moment correlation coefficient
showed significant correlation between ATP5BmRNA and BMI (r = 0.64; P<0.01). There was
lower β-F1-ATPase protein expression (t(11) = 2.597; P = 0.0124) in muscle from obese subjects
compared to that in lean controls (Fig 4B). The calculated translation efficiency for β-
F1-ATPase was lower in obese subjects compared to the lean subjects (Fig 4C; t(11) = 5.251;
P<0.001). Long-term repeated exposure of human myotubes to the NEFA treatments, and
when compared to VEH, resulted in no difference in ATP5BmRNA expression following Lean
NEFA, Lean NEFA(P), or Obese NEFA treatments (Fig 4D). The same NEFA treatments, how-
ever, resulted in a significant effect on β-F1-ATPase protein expression (F(3,20) = 3.115;
P = 0.0492; Fig 4E). Posthoc analysis indicated a significant decrease in Obese NEFA-exposed
myotubes, but not Lean NEFA or NEFA(P) compared to VEH. There was also a significant dif-
ference in β-F1-ATPase protein expression between the two Lean NEFA and Obese NEFA
treated groups (P<0.05). There was a significant effect of treatment on translation efficiency
(F(3,20) = 3.602; P = 0.0314; Fig 4F), and posthoc analysis revealed a significant decrease for
Obese NEFA-exposed myotubes when compared to VEH, but not for Lean NEFA or Lean
NEFA(P). There was a significant difference in translation efficiency between Obese NEFA-
exposed myotubes compared to the Lean NEFA treatment (P = 0.0473). Removal of the Obese
NEFA, although increased GLUT-4 expression (P = 0.0259), did not have a significant effect
on β-F1-ATPase protein expression (P = 0.4910; Fig 4G).
Translation suppression by miR-127-5p
Both miR-101-3p and miR-127-5p have been reported to regulate β-F1-ATPase translation
[19,23], and were investigated in the present study as putative intermediates (S4A Fig). There
was a significant 1.50±0.01 fold increase in miR-127-5p expression (t(11) = 3.551; P<0.01) in
skeletal muscle of obese individuals compared to lean controls (Fig 5A), but no difference in
miR-101-3p expression (t(11) = 1.273; P = 0.1160). The expression of miR-127-5p negatively
correlated with β-F1-ATPase protein translation efficiency (r = -0.6744; P<0.01). In primary
myotubes exposed to NEFA from lean and obese subjects, there was significantly increased
expression of miR-127-5p with Obese NEFA treatment when compared to VEH and the two
Lean NEFA treatments (F(3,20) = 4.919; P = 0.0102), but no difference in Lean NEFA or Lean
NEFA(P) treatments when compared to VEH (Fig 5B). To determine the role of miR-127-5p in
controlling β-F1-ATPase translation, primary myotubes from an obese individual were
exposed to graded concentrations of a miR-127-5p inhibitor. Following transfection, miRNA
and mRNA were quantified. Treatment with the inhibitor did not alter either miR-127-5p
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expression (F(3,20) = 0.09398; P = 0.9625) or ATP5BmRNA expression (F(3,20) = 0.08332;
P = 9683) (Fig 5C). There was a significant effect of inhibitor treatment on β-F1-ATPase pro-
tein expression (F(3,20) = 4.672; P = 0.0125). Exposure to a miR-127-5p inhibitor dose depen-
dently increased β-F1-ATPase protein expression (Fig 5D). There was also a significant effect
of miR-127-5p inhibition on β-F1-ATPase translation efficiency (F(3,20) = 4.941; P = 0.01; Fig
5E). Compared to control, exposure to 50 nM of inhibitor significantly increased translation.
Fig 4. Quantification of ATP5BmRNA and β-F1-ATPase protein expression shows decreased protein
translation in obesity. (A) The mRNA expression for ATP5B and ATP5E are shown, respectively. (B)
Summary of β-F1-ATPase protein expression and representative blots are depicted. Positive bands for β-
F1-ATPase are seen at ~56 kDa and for GAPDH at ~37 kDa. (C) Translation efficiency was compared
between lean (n = 6) and obese (n = 7) subjects. Prolonged NEFA exposure on myotube β-F1-ATPase
translation was determined in skeletal muscle explants (n = 6/group). (D) ATP5BmRNA was quantified for
each NEFA-exposed group, (E) differences in β-F1-ATPase protein expression in response to NEFA
exposure were observed, and (F) translation efficiency was calculated. (G) An additional myotube group was
exposed to Obese NEFA (Pre) and then incubated for an additional five days in normal growth media (Post),
and the cells were analyzed for GLUT-4 and β-F1-ATPase protein expressions. Data shown are means ±SE,
and significance was *P<0.05, **P<0.01, and ***P<0.001 by Student’s unpaired t-test, or by one-way
ANOVA with Tukey’s posthoc analysis.
doi:10.1371/journal.pone.0160057.g004
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Treatments with 10 nM and 100 nM inhibitor did not reach statistical significance (i.e.,
P<0.05).
Genomic and epigenomic mechanisms
The 1 kB region adjacent to the TSS of miRNAs is known to be important for transcription ini-
tiation and is CpG-rich. The methylation status of the 1 kb region was analyzed via high-reso-
lution melt (Fig 6A), and revealed a significant decrease (t(11) = 2.632; P = 0.0117) in the
proportion of methylated CpGs in DNA extracted from the skeletal muscle of obese subjects
compared to those of lean controls. We further analyzed the DNAmethylation profile of the
first two CpG islands via bisulfite sequencing (S5 Fig). Overall, there was a significant effect of
Fig 5. Obesity increases specific skeletal muscle miRNA expression. (A) Expression of miR-127-5p (left) and miR-
101-3p (right) were quantified in lean (n = 6) and obese (n = 6) subjects. (B) Changes in myotube miR-127-5p in response
to repeated exposure to NEFA extracts were determined (n = 6 replicates/group). Alexa Fluor-488 conjugated locked
nucleic acid (LNA) oligos were used to inhibit miR-127-5p in primary myotubes from an obese subject. (C) Response to
graded concentrations of inhibitors (10nM-100nM) are shown for miR-127-5p expression and ATP5BmRNA expression.
(D) Observed responses for β-F1-ATPase protein expression and (E) translation efficiency. Data shown are means ±SE,
and significance was *P<0.05 and **P<0.01 by one-way ANOVAwith Tukey’s posthoc analysis.
doi:10.1371/journal.pone.0160057.g005
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obesity (F(1, 186) = 19.05; P<0.001), CpG site (F(24, 186) = 9.698; P<0.001), and interaction
(F(24, 186) = 7.240; P<0.001). Posthoc analysis identified three of the methylation sites that were
significantly decreased in the skeletal muscle of obese subjects compared to lean: TSS -973
(11.60±6.371%), -882 (12.60±6.007%), -870 (5.400±6.007%) (Fig 6B). The methylation analysis
failed for all obese subjects at site TSS -732, and further review of individual chromatograms
Fig 6. Epigenetic regulation and distribution of miR-127-5p. The 1kB region adjacent to the TSS of miR-
127-5p contains four CpG islands, which may be responsible for sustaining expression of the miRNA. (A)
High Resolution Melt (HRM) was used to analyze overall DNAmethylation status of the 1 kB region upstream
of the miR-127-5p TSS in muscle biopsies in the lean (n = 6) and obese (n = 7) subjects. (B) Results from
bisulfite sequencing of the first two CpG islands of the 1 kB region identified 26 methylation sites in lean
(n = 5) and obese (n = 5) subjects. No results could be obtained for obese subjects at the site indicated by the
arrow. (C) Total RNA was extracted from serum exosomes of lean (n = 6) and obese (n = 6) subjects,
analyzed for miR-127-5p expression (left), and correlation with skeletal muscle expression was determined
(right). Data shown are means ±SE, *P<0.05 and **P<0.01 by Student’s unpaired t-test.
doi:10.1371/journal.pone.0160057.g006
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identified a C!G single nucleotide polymorphism (SNP; rs11623267; S6A Fig), which elimi-
nates cysteine methylation at that site. There is a paucity of information regarding the precise
effect of hypomethylation on miRNA expression, since miRNA ‘promoters’ are generally indis-
tinguishable from coding gene promoters [45]. However, the miRNA control region can be
characterized by H3K4me3 occupation of a methylated CpG island within 1 kb of the TSS [46].
Histone binding of this region, in addition to methylation of the DNA, suppresses transcription
and expression of the miRNAs. Moreover, transcription factor consensus sequence analysis
identified binding sites for the histone-modifying complex CBP/p300 at all significantly altered
methylation sites and the SNP site (S6B Fig).
To expand upon potential clinical applicability of these findings, exosomes extracted from
patient sera collected at the time of the muscle biopsies were analyzed to determine whether
miR-127-5p is present in exosomes and the degree of correlation with skeletal muscle miR-
127-5p expression. Analysis of the small RNAs present in the exosomes revealed the presence
of miR-127-5p (S7C Fig). To determine if the exosomes originated at least partially from mus-
cle tissue, the extracts were probed for Desmin and GAPDH and resulted in positive signals
(S7D Fig). Furthermore, we found that exosomes extracted from the media of the primary
myotube cultures also expressed miR-127-5p (S7E Fig), further supporting a link between exo-
somal miR-127-5p and muscle miRNA. Upon further analysis of miR-127-5p expression in the
exosomes, we found a significant 2.547±0.4609 fold increase (t(11) = 2.934; P<0.01) in obese
subjects compared to lean controls (Fig 6C). The expression of miR-127-5p in exosomes signif-
icantly correlated with skeletal muscle miR-127-5p content (r = 0.9184; P<0.001).
Discussion
We provide in-depth mechanistic insights into how obesity perturbates skeletal muscle protein
metabolism as it relates to the β-F1-ATPase, and advancing previous findings on mitochon-
drial protein metabolism in obesity [3]. Our data suggest that this response in the muscle of
obese individuals is linked specifically to the plasma NEFA profile associated with obese phe-
notype. Furthermore, our findings implicate certain epigenetic mechanisms involving miRNA
regulation in sustaining the impaired translation of muscle β-F1-ATPase involved in energy
metabolism. These innovative findings establish direct effects of plasma NEFA on impairing
the metabolism of β-F1-ATPase, open new avenues of research, and have clinical implications
for understanding mechanisms underlying metabolic dysfunction in muscle (i.e., impaired
muscle ATP production [47]).
There is large variability in protein expression in muscle of obese compared to lean individ-
uals at the single-protein level in general, and mitochondrial level in particular [9]. By focusing
on a single mitochondrial protein and using a series of experiments, we were able to unravel
mechanisms by which circulating NEFA associated with obese phenotype suppress the metab-
olism of β-F1-ATPase (summarized in S8 Fig). Our human data, obtained in a limited number
of subjects, may not be representative of muscle protein metabolism across lean and obese sub-
jects. However, lower total muscle protein synthesis in obese when compared to lean controls
in our study is in line with previous findings in humans [3]. Also, and comparable to earlier
findings in humans [12,48], β-F1-ATPase was lower in muscle from the obese subjects. When
considering the overall lower rate of synthesis of mitochondrial proteins in obesity [3], together
with the reduced translation efficiency of β-F1-ATPase in the obese subjects in the present
studies, it is reasonable to conclude that the rate of synthesis of muscle β-F1-ATPase is
impaired in obesity.
Our findings suggest that a key element contributing to suppressed β-F1-ATPase metabo-
lism in muscle is chronic exposure to lipids associated with the obese phenotype. In the in vivo
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circumstance, these lipids may include plasma NEFA, fatty acids liberated by the action of lipo-
protein lipase in circulating triacylglycerols, or fatty acids released within tissue after stored as
triacylglycerols in skeletal muscle. Regardless of the source of fatty acids, changes in skeletal
muscle protein metabolism may be secondary to initial changes in the plasma lipid milieu.
Undoubtedly, much evidence implicates excessive circulating NEFA in skeletal muscle ectopic
lipid accumulation and lipotoxicity that in turn results in insulin resistance [49,50], and
impaired muscle protein metabolism [32]. However, it is important to note that elevated
plasma NEFA levels alone may not always impair muscle protein synthesis [6], and that the
composition of fatty acids, as documented in the present studies, may be of greater importance
in disrupting muscle protein metabolism. Importantly, circulating lipids associated specifically
with obesity induce aberrant protein synthesis and glucose metabolism in muscle via different
mechanisms. We observed a different pattern in glucose uptake versus protein synthesis fol-
lowing NEFA treatment, and found that removal of NEFA did not recover total protein synthe-
sis or β-F1-ATPase protein abundance in myotubes despite restoring muscle glucose uptake.
Thus, the effects of NEFA exposure on muscle protein metabolism are more persistent than
those on glucose metabolism. Our findings offer a potential explanation as to why, unlike
improvements in plasma glucose homeostasis, β-F1-ATPase protein abundance was not
restored by exercise intervention [48].
Unlike the epsilon subunit of the ATP synthase complex, the beta subunit of the ATP
synthase was differentially regulated between lean and obese subjects at the mRNA expression
level. Our results implicate NEFA-induced miR-127-5p expression in suppressing muscle β-
F1-ATPase translation in obesity, despite an increase in β-F1-ATPase mRNA expression in the
obese subjects. As an extension of the present study, the quantification of miR-127-5p in
plasma exosomes provides a viable marker of β-F1-ATPase metabolism. Hypomethylation of
the miR-127-5p control region emerged as an epigenetic mechanism contributing to the
chronicity of reduced muscle β-F1-ATPase translation in obesity. We identified decreased site-
specific methylation in consensus sequences associated with histone-modifying elements, link-
ing our data to an epigenetic mechanism, which is, however, beyond the scope of this study.
Within the same region, our analysis also revealed a SNP in all obese subjects, removing a cyto-
sine methylation site completely. These findings illustrate a gene-environment interaction that
may be a key mechanism sustaining the increased miR-127-5p expression and subsequently
decreased β-F1-ATPase translation in obesity.
A key strength of our in vitro experiments was the approach of exposing primary myotubes
to the precise distribution of plasma NEFA characteristic of obese individuals. Additionally, by
using NEFA concentrations comparable to those observed in vivo for relatively longer period
of time, our treatment more precisely modeled the obese condition. Therefore, our series of
experiments can link directly ex vivo observations to the in vivo regulation of muscle protein
metabolism in obesity. In concurrence with a recent epidemiological study [51], our results
implicate the distribution of PUFA versus SFA (i.e., PUFA/SFA ratio) rather than total lipid
concentration in the regulation of muscle protein metabolism.
A recent study reported that combined increase in plasma insulin and amino acid concen-
trations sufficiently stimulates protein synthesis of myofibrillar and sarcoplasmic proteins, rep-
resenting the bulk of proteins in muscle, in obese individuals when compared to lean controls
[52]. However, hyperinsulinemia/hyperaminoacidemia did not increase the synthesis of muscle
mitochondrial proteins in obesity [3]. Indeed, as detailed in our experiments, increasing the
abundance of mitochondrial proteins, such as β-F1-ATPase, may be resistant to traditional
interventions due to epigenetic mechanisms activated in obesity via plasma NEFA. Further
investigation into these mechanisms becomes critical in devising scientifically sound interven-
tions that reverse the persistent effects of obesity on muscle protein metabolism.
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We provide in-depth, detailed mechanistic evidence linking plasma NEFA associated with
obese phenotype to suppressed muscle β-F1-ATPase metabolism. These findings extrapolated
from the cell culture model show that the plasma NEFA may play a role in impairing the abun-
dance of muscle β-F1-ATPase in obesity. These effects appear to be independent of the role of
NEFA in impairing muscle glucose metabolism.
Supporting Information
S1 Appendix. Experimental Procedures.
(DOCX)
S1 Dataset.
(XLSX)
S1 Fig. No qualitative changes in growth and differentiation of skeletal muscle explants in
response to NEFA exposure. (A) Myoblast cultures were propagated from skeletal muscle
biopsies, and differentiation of myoblasts to nascent myotubes and mature myotubes was
induced. Myotube differentiation was initiated after six days and continued until NEFA expo-
sure initiation on day 16. NEFA were supplemented every other day for one week. (B) Repre-
sentative photomicrographs are shown for each group at the end of the NEFA exposure period.
Scale bar represents 500 μm.
(TIFF)
S2 Fig. NEFA exposure alters markers of insulin resistance in culture myotubes. (A)
GLUT-4 protein expression. (B) Phosphorylated IRS-1 (Tyr895) expression. (C) Intracellular
triacylglycerol concentration. (D) Free fatty acid content of the culture media at the end of
experimentation. Data shown are means ±SE, n = 6 replicates/group, and significance was
P<0.05, P<0.01, and P<0.001 by one-way ANOVA with Tukey’s posthoc analysis.
(TIFF)
S3 Fig. Concurrent assessment of glucose uptake and nascent protein synthesis in primary
human myotubes. Fluorescent glucose (2-NBDG) and O-propargyl-puromycin (OPP) incor-
poration in primary human myotubes was quantified by flow cytometry. (A) Gating parame-
ters and representative intensity traces. (B) A scatterplot of all cells (black), VEH (red), Lean
NEFA (orange), Lean NEFA(P) (blue), Obese NEFA (green), and recovery group (grey).
(TIF)
S4 Fig. Obesity and skeletal muscle miRNA expression implicated in regulation of β-
F1-ATPase protein. (A) Both miR-101-3p (left) and miR-127-5p (right) can regulate β-
F1-ATPase protein translation (microrna.org). (B) Brightfield photomicrographs and fluores-
cent photomicrographs are shown for the treatment concentrations associated with the data
presented in Fig 5.
(TIF)
S5 Fig. miR-127-5p. A schematic diagram of the CpG islands of the 1 kb region for miR-127-
5p. The 1kB region adjacent to the TSS of miR-127-5p contains four CpG islands, which may
be responsible for sustaining expression of the miRNA.
(TIF)
S6 Fig. Analysis of the miR-127-5p promoter region. Transcription factor binding analysis
revealed consensus sequences for the C/EBP (bold) and p300 (underlined) complex at all sig-
nificantly decreased methylation sites indicated with an asterisk (). The representative
sequencing chromatogram depicts the cause for the lack of methylation data from obese
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subjects at the -732 site was due to a SNP (rs11623267).
(TIFF)
S7 Fig. Control experiments. (A) LC-MS/MS verification of β-F1-ATPase protein in the ~50
kDa band precipitated by the β-F1-ATPase antibody. (B) Bioanalyzer results of RNA ladder
(left) and total RNA extracted from exosomes (right) showing presence of small RNAs. (C)
Amplification curve, melting curve, and DNA agarose gel for qRT-PCR analysis of hsa-miR-
127-5p expression in serum exosomes. (D) Total proteins extracted and Western blot analysis
of desmin (~50 kDa), GAPDH (~37 kDa), and CD-9 (~27 kDa) from serum exosomes. (E)
DNA agarose gel, amplification curve, and melting curve for qRT-PCR analysis of hsa-miR-
127-5p expression in exosomes extracted from myotube culture media.
(TIFF)
S8 Fig. Model of β-F1-ATPase Translation Regulation in Obesity. Genetic and epigenetic
factors unmask transcription of miR-127-5p, which can then bind to the 3’ UTR of the ATP5B
mRNA and block ribosomal translation machinery from accessing the transcript.
(TIF)
S9 Fig. Western blots. Original, uncropped, and unadjusted western blots for the data pre-
sented in the Figures in the Results Section.
(TIF)
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